Rep

Point of Care Strep Tests Speed Treatment, Lower Costs

Beta-hemolytic group A streptococcus (S. pyogenes) is the most common bacterial agent associated with upper respiratory tract infections. Although it usually involves mild symptoms (such as headache, fever or abdominal pain) if left untreated streptococcal infection can worsen and become life-threatening. Early diagnosis and treatment of group A streptococcal pharyngitis has been shown to red...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented AtherOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

BETHESDA, Md., July 5, 2007--In this weeks issue of Science,researchers from the National Institute of Environmental HealthSciences (NIEHS) and Umeö University in Sweden report animportant discovery about a critical new role that an enzyme calledDNA polymerase epsilon plays in replicating DNA in higher organismssuch as yeast and perhaps even humans. The study places us one ste...

Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA(SWX:COPN) announced today positive preliminary results from itsphase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ininfectious diarrhoea. CB-01-11 is a broad spectrum, semi-syntheticantibiotic that is not absorbed when taken in tablet form. Throughthe use of Cosmo's MMX(tm) technology, wh...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,Incorporated (Nasdaq: CYTK) announced results from the analyses ofthree Phase II clinical trials of ispinesib administered asmonotherapy, one in patients with hepatocellular cancer, one inpatients with melanoma, and one in patients with hormone-refractoryprostate cancer. I...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection

MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytochroma Inc.announced today positive data from a Phase I clinical trial ofCTA018 Injection. The initial top-line results from this trialshowed that CTA018 was safe and well tolerated. Complete studyresults are expected in August 2007. The recently completed Phase I trial was an open label,placebo-controlled, randomized study of CTA018 In...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profilingin Diabetic Patients BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel(SWX: SPPN) today announced that it has reached another significantmilestone in the development of its family of renin inhibitors withthe successful completion of a Phase IIa proof-of-concept clinicaltrial with SPP635 for the treat...

Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced positive resultsfrom a recently-completed multi-dose pharmacokinetic study ofvaginally-administered lidocaine, which the Company is developingto prevent and treat dysmenorrhea. This 42-subject study was designed to provide data on bloodlevels associated with the Company's bioadhesiv...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayannounced promising data from the six-month, open-label extensionof its completed Phase IIa clinical trial with arimoclomol in ALSvolunteers. While the clinical trial was not placebo-controlled,arimoclomol at a 1...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. today announced results from three Phase I trialsstudying REP8839, a novel topical antibiotic that has shown potentin vitro activity against major skin pathogens includingmethicillin-resistant S. aureus (MRSA). The results of the Phase Itrials show that topically applied REP8839 appears safe,well-tolerated and asso...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) announced today that an interimanalysis of a pregnancy study comparing the efficacy of CRINONE(R)8% (progesterone gel) to compounded intramuscular progesterone(IMP) injections is now available online and will be published inFertility and Sterility, the journal of the American Society forReproductive...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced positive clinical results in threeCompany-sponsored studies of its investigational drug, Nasulin(TM),an intranasal insulin spray. The data were presented this pastweekend at the American Diabetes Association 67th ScientificSessions in Chicago. In a pl...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research andMarkets (http://www.researchandmarkets.com/reports/c60415) hasannounced the addition of Looking at Chiral Technologies to theiroffering. The advancements in molecular research and continued untiringefforts of the research industry to develop better more preciselyapplicable Pharmaceuticals as well as agro compounds would have not...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/IIextension clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In this one-year,8-subject extension clinical trial...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB)today announced that data relating to its proprietaryPC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment ofType 2 diabetes will be presented at the 67th ScientificSessions of the American Diabetes Association (ADA) to beheld June 22-26, 2007 in Chicago, IL. The ADA's annualScientific Sessions meeting is one of the larges...

Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs

BOULDER, Colo.--(BUSINESS WIRE)--Jun 20, 2007 - Array BioPharmaInc. (Nasdaq: ARRY) announced new Phase 1 clinical data on its MEKinhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. These resultswere presented at the Annual European Congress of Rheumatology(EULAR) in Barcelona, Spain, and at the International Associationof Inflammation Societies' (IAIS) 8th World Congress onInflammation in...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Study Fails to Meet Primary Endpoint of Improvement in OverallSurvival WESTMINSTER, Colo., June 19, 2007 /PRNewswire-FirstCall/ --Allos Therapeutics, Inc. today announced top line results fromENRICH, the Company's pivotal Phase 3 study of Efaproxyn (efaproxiral) plus whole brain radiation therapy (WBRT) in womenwith brain metastases originating from breast cancer. The studyfailed to achi...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference

BARCELONA, SPAIN and SEATTLE, WA -- (MARKET WIRE) -- June 14,2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today isreporting data from the dose escalation arm of the ongoing PhaseI/II clinical study of tgAAC94 in patients with inflammatoryarthritis. Philip J. Mease, M.D., clinical professor at theUniversity of Washington School of Medicine, chief of rheumatologyclinical research a...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today released top-line findingsfrom its six month study of Proellex in the treatment ofendometriosis. This study, conducted in Europe, enrolled 39premenopausal women and has completed six months of dosing. Thestudy included three dose levels of Proellex(TM) as well as apositive control arm. The po...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates, SNS-595 and SNS-032, at the 12thCongress of the European Hematology Association (E...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...

Dynogen Reports Positive Results in Phase 1B GERD Study

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 7, 2007 - DynogenPharmaceuticals, Inc. reported positive results of its randomized,double-blind, placebo-controlled Phase 1b trial of DDP733 forgastroesophageal reflux disease (GERD). The study was designed todemonstrate proof-of-concept for DDP733 as a treatment fornocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achievedstatistical significance over p...

Indevus Reports Positive Data From Phase III NEBIDO Trial

Compound Achieves All Key Endpoints for Both Efficacy and Safety LEXINGTON, Mass., June 07, 2007 /PRNewswire-FirstCall/ --Indevus Pharmaceuticals, Inc. today announced final results fromits Phase III pharmacokinetic trial for NEBIDO (testosteroneundecanoate), a long- acting injectable testosterone therapy underdevelopment for the treatment of male hypogonadism which theCompany licensed fr...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that initial results from a Phase I studywith the Company's humanized anti-MUC1 monoclonal antibody (hPAM4),labeled with...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - GloucesterPharmaceuticals, Inc., a privately held cancer therapeuticsdevelopment company, today announced that data for romidepsin as atreatment for cutaneous T-cell lymphoma (CTCL) and peripheralT-cell lymphoma (PTCL) were presented at the American Society ofClinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.The data presented...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

-- Genotypically Optimized Dosing Results in Improved Toleranceand Evidence of Anticancer Activity -- MELBOURNE, Australia, and MENLO PARK, California U.S.A. June 04,2007-ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announcedtoday the presentation of data from its Quinamed (amonafidedihydrochloride) phase 1/2a dose-escalation study, designed toidentify a genotypically optimis...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Ratein Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of OralAzacitidine Exelixis Reports Integrated Data From Phase II Clinical Trialsof XL999 at ASCO Clinical Data Reported on Vidaza in Hematologic Malignancies andAdva...

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) announced topline results of asix month U.S. Phase 3 study of Androxal(TM), an oral drug beingdeveloped to restore normal testicular function in men withsecondary hypogonadism. Further, Androxal demonstratesnon-inferiority in all the endpoints of the study, compared toAndrogel(R), a cream which is t...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...